AstraZeneca's blood cancer drug meets main goal in late-stage trial

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.

from Healthcare/Biotech-Industry-Economic Times http://bit.ly/2WriWxB
via IFTTT